Skip to main content

Table 1 Clinico-pathological characteristics of patients

From: Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment

Variable

No

%

Age

  

Median (year)

65

Range (year)

46–77

Gender

  

 Male

27

57.4

 Female

20

42.6

Histology

  

 Classical adenocarcinoma

43

91.5

 Mucinous adenocarcinoma

4

8.5

Side

  

 Right

25

53.2

 Left

22

46.8

PS ECOG

  

 0

4

8.5

 1

24

51.1

 2

19

40.4

No. of metastatic sites

  

 1

6

12.8

  ≥ 2

41

87.2

K- or N-RAS

  

 Mutated

13

27.7

 Wild-type

34

72.3

BRAF

  

 Mutated

4

8.5

 Wild-type

43

91.5

FGFR4 p.G388R

  

 No

32

68.1

 Yes

15

31.9